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Abstract
Background: To stimulate use of generic medicines a combination of supply and demand side mechanisms are
employed in the Latvian reimbursement system. It is reported that patients have high out-of-pocket pharmaceutical
spending and that they overpay by not choosing generic medicines. Patient preferences may be an important
obstacle in implementing generic policy. Objective of this study was to assess awareness, opinions and experience
of the Latvian population regarding use of generic medicines.
Methods: Survey of representative sample of the population of Latvia (n = 1005) aged 18–74 was conducted in
March 2015. The survey was distributed in Latvian and Russian languages using Computer Assisted Web Interviews.
Associations between experience with generic medicines, preference for medicines, and sociodemographic variables
were tested with Pearson Chi-square statistics. Associations between the previous experience and information given by
different sources versus choice between medicines were tested with Spearman’s correlation test.
Results: 72.3% of the population were informed about generic medicines. Men (66.9%) and respondents with primary
or secondary education (58.3%; 69.3%) were less informed compared to total (72.3%). From those who recalled using
generic medicines (n = 441), 94.4% evaluated their experience as positive or neutral. Despite this, only 21% of the
population would opt for generic medicines. The strongest preference for brand-name medicines was in the age
group > 55 (40.5%). Opinion of a physician was the most important factor when choosing between generic and brand-
name medicines (88.7%). The more positive the information provided by general practitioners, physician specialists,
pharmacists, family members, friends and internet is perceived, the more likely respondents are to choose generic
medicines (p < 0.001).
Conclusion: This study demonstrates that people in Latvia are aware of generic medicines but only a minority of the
population would choose them when presented with a choice. It is therefore important that health care professionals
provide objective and unbiased information about generic medicines to their patients. Interventions should aim to
reach groups that are less informed and to improve providers’ understanding and communication with patients about
generics.
Introduction
Use of generic medicines (GM) is an important tool to
stimulate competition in the pharmaceutical market and
reduce the cost of medicines [1, 2]. The consumption of
GM in Europe differs among countries, and it is esti-
mated to range between 10 and 90% of the total medi-
cines market [2]. Latvia has a relatively high penetration
rate of GM (64% by volume and 33% by value) [3]. To
promote use of GM, a combination of supply and
demand side mechanisms [4, 5] such as reference pri-
cing, international non-proprietary name (INN) pre-
scribing, generic substitution [6] and public information
campaigns is employed within the Latvian reimburse-
ment system. Prescription medications are reimbursed
as part of a benefit package in a single-purchaser na-
tional health system funded by general tax revenues.
The National Health Service of the Republic of Latvia
(NHSRL), an administrative institution of the Ministry
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of Health, produces and maintains a positive outpatient
reimbursement list [7]. The list contains approximately
1600 medications and accounts for 39% of total pharma-
ceutical expenditure. According to the severity of illness
and dependency on treatment, medications in the list
have three levels of reimbursement - 100, 75% or 50%
[6–8]. For the medications that are reimbursed less than
100%, patients cover the remaining cost. Medicines in the
reimbursement list are classified into three groups – A, B
and C. List A is a reference list of interchangeable medica-
tions, but lists B and C contain non-interchangeable,
mostly patented products [6–8]. Reference pricing, INN
prescribing and mandatory generic substitution are used
to encourage use of reference products within the list A.
The current regulation specifies that unless there is a doc-
umented medical need, in the case where the patient or
the prescriber opposes generic substitution, the patient
must cover the difference in price between the reference
product and the chosen product or in some cases even
pay the full price of the chosen medicine. Although access
to medicines can partly be hampered by the limited num-
ber of medicines covered by the reimbursement list and
levels of reimbursement, the NHSRL has estimated that
within the Latvian reimbursement system, patients in
co-payments overpay several millions a year for medicines
by not choosing cheapest available GM [9]. Patients’ pref-
erences might be an important obstacle in implementing
effective generic policy [10, 11]. Some individual studies
have shown that lay people have no objections to using
GM [12] and that they perceive no difference between
GM and brand-name medicines [13, 14]. However, the au-
thors of two systematic reviews concluded that high pro-
portion of lay people tend to believe that GM are of lower
quality and less effective than brand-name medicines as a
result they may feel negatively about generic substitution
[15, 16]. The analysis of patients’ opinions has suggested
that the most common reason for refusing GM was the
customers’ positive experiences with medicines they had
used previously, as well as their wish to talk with their
doctor before accepting substitutes [17] In Latvia
out-of-pocket spending for pharmaceuticals is the second
highest among Organization for Economic Co-operation
and Development (OECD) countries (39%) [18], many
people report unmet health needs [19] and financial diffi-
culties to obtain the prescription medicines they need to
manage chronic conditions [20]. Given this situtation the
study regarding population’s choices and preferences of
GM may offer valuable insights to strengthen generic
policy and improve access to medicines.
Aim of the study
The aim of this study was to assess awareness, opinions
and experience of the general population regarding use
of GM in Latvia.
Method
The respondents who participated in the study (n = 1005)
represented the adult general population of Latvia aged 18
to 74. The sample was selected using the database of the
research company SKDS and composed to meet the
characteristics of a nationally representative sample. To
adjust precisely to the criteria of a representative sample,
data were weighted according to four parameters – gen-
der, age, nationality and place of residence, according to
the data in the electronic system of the Population Regis-
ter maintained by the Office of Citizenship and Migration
Affairs. The survey was distributed in Latvian and Russian
languages using Computer Assisted Web Interviews as
part of the monthly Web-Omnibus survey. The data col-
lection took place in March 2015. The dataset generated
and analysed during the current study is available in the
Open Science Framework repository.
With the authors’ permission, we developed the
survey based on the questionnaire by Drozdowska
and Hermanowski [21]. The questionnaire was trans-
lated into Latvian; we performed a cognitive testing
of the questionnaire (n = 10) – questions were evalu-
ated in terms of quality and comprehension.
In addition to demographic information, the survey
contained the following questions: 1) awareness of GM
(“Did you know about the existence of GM?”); 2) experi-
ence with GM (“What is your experience with GM? -
positive/more positive; neutral; negative/more negative;
hard to say”); 3) preference for GM vs brand-name med-
icines (“If presented with choice, which one would you
chose – GM or brand-name medicine?”); 4) factors of
importance when choosing generic or brand-name med-
icines (“When choosing medicines, what is the import-
ance of the following factors – price; producer of a
medicine; country in which medicine is produced;
information in press, TV and radio; information on the
Internet; opinion of a physician; opinion of a pharmacist;
opinion of family members; opinion of friends and rela-
tives; my own experience?”; 5) information about GM
provided by different sources (GP; physicians-specialists;
pharmacists; relatives and friends; information in press,
information on the Internet – positive/more positive;
neutral; negative/more negative; no information).The an-
swers were measured on a Likert scale (for the purpose
of the analysis, we combined some answers, e.g. “very
important” and “rather important” was combined as
“very/rather important” and “positive” and “rather posi-
tive” was combined as “positive/rather positive”).
Data analysis was performed in SPSS v.25 for
Windows. The study employed descriptive statistics
methods. To test associations between the following
variables - experience with GM, preference for medi-
cines, as well as sociodemographic variables - Pearson
Chi-square statistics with significance level p < 0.05 was
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used. To normalize data in Chi-square hypothesis test-
ing, we used a standardized residuals ratio (difference
between the observed count and the expected count and
standard deviation of the expected count). The results
were interpreted as follows: if the residual is less than −
1.96, the cell’s observed frequency is less than the ex-
pected frequency; if the residual is greater than 1.96, the
cell’s observed frequency is greater than the expected
frequency.
To test associations between the previous experience
and information given by different sources versus choice
between medicines, we used Spearman’s correlation test.
Results
Awareness about generic medicines
A large part of the population in Latvia (72.3%) was in-
formed about GM (Table 1). There were more informed
respondents in the female group (77.3%) than in the
male group (66.9%) and within an age group > 55 years
(76.9%), if compared to the total number of the informed
group. 22.5% of the population were not informed about
the existence of GM, and more of those who were not
informed were found in young people group (age group
18–24 years) – 35.0%.
Experience with generic medicines
From those respondents who have used GM (n = 441;
44%), the majority (55.7%) recognized their experience
with GM as positive or more positive than negative, and
38.7% rated their experience as neutral (Table 2). Only
5.7% described their experience as negative or rather
Table 1 Study population characteristics in terms of knowledge and preferences of GMa
Sociodemographic characteristics Are informed about GM Are not informed about GM No opinion
From total (n = 1005) 727 (72.3%) 226 (22.5%) 52 (5.2%)
Gender
Female, n = 528 408 (77.3%) 96 (18.2%) 24 (4.5%)
Male, n = 477 319 (66.9%) 130 (27.3%) 28 (5.8%)
Age
18–24, n = 120 71 (59.2%) 42 (35.0%) 7 (5.8%)
25–34, n = 207 155 (74.9%) 47 (22.7%) 5 (2.4%)
35–44, n = 188 141 (75.0%) 39 (20.7%) 8 (4.3%)
45–54, n = 192 130 (67.7%) 50 (26.0%) 12 (6.3%)
> 55, n = 298 229 (76.9%) 49 (16.4%) 20 (6.7%)
Education
Primary, n = 24 14 (58.3%) 10 (41.7%) 0
Secondary, n = 339 235 (69.3%) 85 (25.1%) 19 (5.6%)
Higher, n = 642 478 (74.5%) 131 (20.4%) 33 (5.1%)




From total (n = 1005) 211 (21.0%) 287 (28.6%) 507 (50.4%)
Age
18–24, n = 120 24 (20.2%) 24 (19.3%) 72 (60.5%)
25–34, n = 207 43 (20.8%) 47 (22.7%) 117 (56.5%)
35–44, n = 188 47 (25.0%) 41 (21.8%) 100 (53.2%)
45–54, n = 192 50 (26.0%) 55 (28.6%) 87 (45.3%)
> 55, n = 298 47 (15.7%) 121 (40.5%) 130 (43.8%)
Nationality
Latvian, n = 586 107 (18.3%) 174 (29.7%) 305 (52.0%)
Other, n = 419 104 (24.8%) 113 (27.0%) 202 (50.4%)
aBolded text refers to responses that differ significantly from the total (adjusted standardized residuals value > 1.96 or < − 1.96)
Table 2 Experience with generic medicines, n=441b
n %
Negative or more negative than positive 25 5.7
Neutral 170 38.7
Positive or more positive than negative 246 55.7
Total 441 100.0
bRespondents who have not used GM were excluded from the analysis
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negative. No statistically significant changes were de-
tected among different gender and age groups.
Preferences of the respondents
As seen in Tables 1, 21.0% of the respondents would
rather or definitely choose GM; 28.6% would rather or
definitely opt for brand-name medicines, but 50.4% of
the population did not have an opinion in this respect.
The strongest preference for GM was in the age group
45–55 (26.0%), whereas the strongest preference for
brand-name medicines persisted in the age group > 55
(40.5%). Those who would prefer brand-name medicines
were more often found in the group of other nationalities
(Russians, Belarussians, Ukrainians, Poles, Lithuanians,
etc.) (24.8%), compared to Latvians (18.3%).
Those who would prefer GM were more among
respondents who have had positive/more positive than
negative previous experience with GM (32.2%) (Table 3).
Sociodemographic factors (sex, age, education and na-
tionality) were not statistically significant to differenti-
ate the respondents according to their previous
experience with GM. The more positively respondents
assessed their experience with GM, the more willing
they were to choose GM instead of brand-name
medicines (Spearman’s rho = 0.4, p < 0.001).
The more positively respondents assessed their
experience with GM, the more willing they were to
choose GM instead of brand-name medicines (Spearman’s
rho = 0.4, p < 0.001) (see Table 4).
Factors of importance when choosing between generic
and brand-name medicines
As seen in Fig. 1, four factors of the highest importance
when choosing between GM and brand-name medicines
were: [1] opinion of a physician – 88.7% of the respon-
dents considered it as very or rather important; [2] pre-
vious experience with GM (87.1%), [3] price (85.2%), [4]
opinion of a pharmacist – 81.5%.
Information about generic medicines from different
information sources
As shown in the Table 5, pharmacists provided more
positive information about GM (47.2%), if compared to
other sources of information in Latvia. Physicians of
different specialties provided more negative information
(7.7%), compared to the other sources.
Small and medium correlation was found between in-
formation about GM from several sources and willing-
ness to choose GM (see Table 6). The more positive
information about GM was received from the following
information sources, the more likely respondents were
to choose GM instead of brand-name medicines - general
practitioners (Spearman’s rho = 0.16), physicians from dif-
ferent specialties (Spearman’s rho = 0.18), pharmacists
(Spearman’s rho = 0.15), family members (Spearman’s
rho = 0.34), relatives and friends (Spearman’s rho =
0.35), as well as the Internet (Spearman’s rho = 0.18),
p < 0.001.
Discussion
This is the first study in Latvia that examines awareness,
experience and opinions of the population about GM.
The results of the study showed that the majority of the
population is informed about the availability of GM as
an alternative to brand-name medicines. Women, higher
educated and older patient groups were more informed
compared to other groups. This might be explained by
the fact that women and higher-educated people tend to
have higher health literacy [22–25], and older people in
Latvia are more exposed to the medicines’ reimburse-
ment system in general, which distinguishes between
generic and brand-name medicines, and to the NHSRL
public campaigns promoting GM. The fact that men,
people with primary and secondary education and
nationalities other than Latvian are less informed may
suggest that public information is not reaching these
groups.
Approximately 44% of respondents in our study
recalled previous experience with using GM. The actual
number might be higher, as users might not always be
aware whether they are using generic or brand-name
medicines. The results show that the majority of those
who recalled using GM rated their experience as positive
or neutral. Only 5.7% of those surveyed reported their
experience of using generics as negative. This finding is
Table 3 Associations between experience and preferences, n=441c




Negative/more negative than positive experience with GM 0 (0.0%) 2 (8.0%) 23 (92.0%)
Neutral experience 32 (18.7%) 87 (50.9%) 52 (30.4%)
Positive/more positive than negative experience with GM 79 (32.2%) 122 (49.8%) 44 (18%)
cBolded text refers to responses that differ significantly from the total (adjusted standardized residuals value > 1.96 or < −1.96)
Table 4 Positive experience and willingness to choose GM
Positive experience
with GM
Willingness to choose GM, (Spearman’s rho) 0.4
Sig. (2-tailed) 0.0001
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consistent with results reported by Drozdowska and
Hermanowski in the Polish population where the major-
ity were satisfied with using GM [21]. Negative experi-
ences with GM safety or efficacy have been reported in
other studies [15, 16]. This experience is not consistent
with clinical studies; systematic reviews of equivalence
between generics and brand-name medicines does not
confirm differences in efficacy or safety [26, 27]. It is
possible that patients’ negative experience of lower
efficacy or side effects with GM might be influenced by
nocebo effects [28].
Despite the high awareness and positive or neutral
experience of those who had used GM, only about one
fifth of the total number of respondents would prefer
using GM, if they had to make a choice between GM
and brand-name medicines in the future. This is differ-
ent from the situation in Poland, where more than a half
of the respondents were willing to opt for GM [25]. A
systematic review by Colgan et al. also highlighted that a
significant proportion of consumers held negative
attitude towards GM which is a barrier for uptake of
GM [16]. The negative attitude may be related to the
fact that consumers do not consider GM as equal alter-
natives to brand-name medicines [29] and hold different
myths about them [15]. Consistently with studies from
Finland and Poland [17, 21], we did not find any associa-
tions between gender and preferences towards GM.
In the Latvian context, the strongest preference for
brand-name medicines was in the age group over 55
years. This finding is unfortunate as most common
chronic conditions are prevalent in this age group and
representatives of the group might be beneficiaries of
the pharmaceutical reimbursement system which pro-
motes use of GM. These findings of preference for
brand-name medicines and less willingness to use GM
among older people are consistent with findings in other
European countries like Finland, Switzerland and
Belgium [17, 30, 31]. It would be useful to further ex-
plore reasons and identify best solutions to address mis-
trust towards GM in this age group.
Similar to other researchers [21, 15], we also found
that the more positive GM users rated their experience,
the more willing they were to choose GM if presented
with a choice.
In our study, physician specialists were found to pro-
vide more negative information about GM compared to
other information sources. It would be useful to explore
reasons for this in further research. Possible explanations
might be lack of knowledge about the concept of bio-
equivalence or specialists’ close relationships with the
pharmaceutical industry. Studies have suggested that
the payments from the pharmaceutical industry are
associated with preferences for brand-name medicines
[32, 33]. The systematic review by Dunne and Dunne
Fig. 1 Factors of importance when choosing between GM and brand-name medicines, %, n = 1005







Pharmacist 47.2 23.1 4.7 25.0
General practitioner 34.1 19.4 3.9 42.6
Physicians 28.0 18.2 7.7 46.1
Internet 26.4 15.1 5.4 53.1
TV, radio, mass media 18.6 16.4 6.4 58.6
dRespondents who were not informed about the existence of GM were excluded from the analysis
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suggests that physicians play a particularly important
role in ensuring consumers’ confidence in GM [15].
The study that examined the relationship between pa-
tient beliefs and communication about GM with their
providers, also concluded that the willingness to use
GM is associated with positive communication with
providers [34].
This study has the following limitations – as the
survey was distributed as Computer Assisted Web
Interviews, it did not reach the part of the population
not using the Internet. It is estimated that approximately
21% of the Latvian population do not use Internet on a
regular basis. The proportion of Internet nonusers differ
significantly among the age groups. Within the age
group 18–44 about 4% do not use Internet regularly,
while within the age group 45–64 the share constitutes
28%, and within the age group 65–74 those are 64.5%
[35]. To adjust to the criteria of a representative sample,
data were weighted according to four parameters
(gender, age, nationality and place of residence), but
were not weighted according to education, therefore, the
sample included a higher proportion of population with
higher education than the general population in
Latvia. It might have had impact on the study results.
For instance, there are studies suggesting that popula-
tion with higher education have more positive attitude
towards GM and are more likely to choose generic
substitution [15, 36].
Conclusion
Although the majority of people in Latvia are informed
about the existence of GM, and most of the users of GM
rate their experience as positive, only about one fifth of
the population would opt for GM. Certain groups like
men, people with nationalities other than Latvian, people
with primary and secondary education and elderly
people were less aware or willing to use GM compared
to other society members. This is a worrisome fact
showing that there is a need to reconsider information
that consumers receive from different information
sources about GM. Choice of GM instead of usually
more expensive brand-name medicines is particularly
important in Latvia where a large part of the population
lack access to medicines. As people in Latvia trust physi-
cians and pharmacists in their choice between medicines,
it is important that they provide objective and unbiased
information about GM, as well as promote their use.
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